期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生理药代动力学模型及其在药物相互作用研究中的应用 被引量：3

Characteristics and applications in drug-drug interaction of physiologically based on pharmacokinetic model
原文传递
导出
摘要 生理药代动力学模型(PBPK model)在毒理学和药理学领域得到越来越多的关注和应用,如用于药物-药物相互作用(DDI)等研究。DDI会影响药物的安全性、有效性、药物标识及选择药物联用的合理性,其在药物研发和上市后研究中已成为临床药理研究的重要组成部分。基于模型的分析方法被证明是评价DDI作用的有力工具。本文对PBPK模型的特征及其在DDI研究中的应用现状进行阐述。 Currently, physiologically based pharmacokinetic （PBPK） model has been gaining increasing attention and application in toxicology and pharmacology, such as the application in drug- drug interaction （DDI）. DDI, which affects safety, effectiveness, drug identification as- sociated with rationality of the combinational therapy, has become an im-portant part of clinical pharmacology studies in drug development. Model-based analysis method is proved to be a powerful tool for evaluation of DDI. Therefore, we review the characteristics of PBPK model and its ap-plications in the study of drug - drug interaction.
作者 周颖 胡蓓 王洪允 江骥
机构地区 中国医学科学院北京协和医院临床药理研究中心
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2013年第9期706-709,共4页 The Chinese Journal of Clinical Pharmacology
关键词 生理药代动力学 药物相互作用 模型 physiologically based pharmacokinetic model drug-druginteraction modeling
分类号 R969.1 [医药卫生—药理学] P069.2 [天文地球]
  • 相关文献

参考文献19

  • 1Teore11 T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration [ J]. Arcb lnt Pharmacodyn Tber, 1937 , 57:202 - 205.
  • 2Nestorov I. Whole body pharmacokinetic models [ J 1. Clin Phar- macokinet, 2003, 42:883- 908.
  • 3Andersen ME. Toxicokinetic modeling and its applications in chemi- cal risk assessment[ J]. Toxicol Lett, 2003 , 138:9 - 27.
  • 4Clewell HJ, andersen ME. Applying mode - of - action and phar- macokinetic considerations in contemporary cancer risk assessments : an example with trichloroethylene [ J]. Crit Rev Toxicol, 2004 , 34 : 385 - 445.
  • 5Chiu WA, White P. Steady - state solutions to PBPK models and their applications to risk assessment I : Route - to - route extrapola- tion of volatile chemicals [ J]. Risk Anal, 2006, 26:769-780.
  • 6Simmons JE, Evans MV, Boyes WK. Moving from external expo- sure concentration to internal dose:duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose [J]. J Toxicol Environ Health A, 2005, 68:927-950.
  • 7Yuan LG, Luo XY, Zhu LX, et al. A physiologically based phar- macokinetic model for valnemulin in rats and extrapolation to pigs [J]. J Vet Pharmacol Ther, 2011, 34:224-231.
  • 8Pang KS, Durk MR. Physiologically - based pharmacokinetic mod- eling for absorption, transport, metabolism and excretion [ J ]. J Pharmacokinet Pharmacodyn, 2010 , 37 : 591 - 615.
  • 9Krishnan K, Haddad S, B61iveau M, et al. Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures [ J ]. Environ Health Perspect, 2002,110:989 -994.
  • 10Food and Drug Administration, USA. Guidance for industry:In vivo drug metabolism drug interaction studies - study design, data analy- sis, implications for dosing, and labeling recommendations [ EB/ OL ]. http://www, fda. gov/ohrms/dockets/98fr/981001Gd. pdf, 2012-02-05.

同被引文献21

  • 1Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane trans- porters in drug development [J]. Nat Rev Drug Discov, 2010,9:215 -236.
  • 2FDA. Guidance for industry: drug interaction studies - study de- sign, data analysis, implications for dosing, and labeling recom- mendations [EB/OL]. http://www, fda. gov/downloads/drugs/ guidanees/uem292362 pdf, 2015-05-23.
  • 3Endres CJ, Hsiao P, Chung FS, et al. The role of transporters in drug interactions [ J ]. Eur J Pharm Sci, 2006,27:501 - 517.
  • 4Karlgren M, Ahlin G, Bergstrom CA, et al. In vitro and in silico strategies to identify OATP1 B1 inhibitors and predict clinical drug - drug interactions[ J]. Pharm Res, 2012,29:411 -426.
  • 5Gertz M, Cartwright CM, Hobbs M J, et al. Cyelospofine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug - drug in- teraction potential [ J ]. Pharm Res, 2013,30:761 - 780.
  • 6Yoshida K, Maeda K, Sugiyama Y. Transporter - mediated drug - - drug interactions involving OATP substrates : predictions based on in vitro inhibition studies [ J]. Clin Pharmacol Ther, 2012,91: 1053 - 1064.
  • 7Fenneteau F, Turgeon J, Couture L, et al. Assessing drug distribu- tion in tissues expressing P - glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination [ J]. Theor Biol Med Model, 2009, 6:2.
  • 8Jones HM, Barton HA, Lai Y, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter - mediated disposition in humans from sandwich culture human hepatocyte data [ J 1. Drug Metab Dispos, 2012,40 : 1007 - 1017.
  • 9Watanabe T, Kusuhara H, Maeda K, et aL Physiologically based pharmaeokinetie modeling to predict transporter - mediated clearance and distribution of pravastatin in humans [ J]. J Pharma- col Exp Ther , 2009,328:652 - 662.
  • 10Varma MV, Lai Y, Feng B, et al. Physiologically based modeling of pravastatin transporter - mediated hepatobiliary disposition and drug - drug interactions[ J ]. Pharm Res, 2012,29:2860 - 2873.

引证文献3

二级引证文献12

中国临床药理学杂志
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部